Clinical Trials Logo

Vascular Calcification clinical trials

View clinical trials related to Vascular Calcification.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05434676 Active, not recruiting - Clinical trials for Peripheral Arterial Disease

SOLUTION Trial in China

Start date: June 15, 2021
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, single arm study, to support the safety and effectiveness assessment of the Shockwave Medical Peripheral IVL System applied to Chinese patients

NCT ID: NCT05433376 Active, not recruiting - Clinical trials for Coronary Artery Disease

SOLSTICE Trial in China

Start date: April 15, 2021
Phase: N/A
Study type: Interventional

This is a small sample size clinical trial in Chinese population to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions prior to stenting.

NCT ID: NCT05030831 Active, not recruiting - Clinical trials for Pseudoxanthoma Elasticum

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Start date: April 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficiency.

NCT ID: NCT04956120 Active, not recruiting - Clinical trials for Vascular Calcification

Effect of Citrate Dialysis on Vascular Calcification

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to determine whether hemodialysis with citrate slows the progression of vascular calcification. Participants will be dialyzed with one of two standard dialysis solutions, one with and one without citrate, for 12 months and then switched to the other solution for 12 months. Vascular calcification will be measured on mammograms that will be performed at 6-month intervals and additional blood samples will be obtained at 6-month intervals.

NCT ID: NCT02598635 Active, not recruiting - Clinical trials for Vitamin D Deficiency

Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis

Start date: October 2015
Phase: Phase 4
Study type: Interventional

Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal dialysis and 25(OH) vitamin D deficiency.

NCT ID: NCT02431234 Active, not recruiting - Clinical trials for Arteriosclerosis Obliterans

Arterial Calcification in the Diabetes

DIACART
Start date: February 2014
Phase:
Study type: Observational

The blood concentration of the protein RANKL could be predictive of the calcification of the leg arteries, which is a major complication occurring during diabetes. The objective of the DIACART study is to show that blood RANKL concentration predict the progression of calcification of the leg arteries in diabetic patients, independently of other cardiovascular risk factors.

NCT ID: NCT01922804 Active, not recruiting - Clinical trials for Metabolic Bone Disorder

Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification

K2vita
Start date: July 2013
Phase: N/A
Study type: Interventional

The aims of the present study are to investigate the effect of vitamin K2 on bone turnover, bone mass, bone structure, glucose metabolism, and arteriosclerosis. Osteoporosis, diabetes, metabolic syndrome and cardiovascular disease are common diseases that affect large groups of people in the Western world. Our hypotheses is that vitamin K2 (MK-7) reduces undercarboxylated osteocalcin in postmenopausal women and reduces bone turnover and increases bone mineral density; increases insulin sensitivity and decreases indices of arterial calcification.